Tag: Atrial Fibrillation
-
DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation
New Findings Question SGLT2 Inhibitors for Post-Ablation AF Recurrence In a development that surprises many in the cardiology community, the DARE-HF trial examined whether the SGLT2 inhibitor dapagliflozin could reduce the burden of atrial fibrillation (AF) after catheter ablation. Conducted in patients who recently underwent ablation for AF, the study aimed to determine if adding…
-
DARE-AF: Dapagliflozin Fails to Reduce AF Recurrence After Catheter Ablation
Overview: DARE-AF Trial Questions SGLT2 Inhibition After Ablation The latest findings from the DARE-AF trial suggest that dapagliflozin, an SGLT2 inhibitor, does not reduce the burden of atrial fibrillation (AF) after catheter ablation. Conducted in a diverse patient population, the study aimed to determine whether adding dapagliflozin to standard post-ablation care could lower AF recurrence…
-
DARE-AF Trial: Dapagliflozin Fails to Reduce AF Burden After Ablation
Overview: Aiming to Lower AF Recurrence With SGLT2 Inhibition The DARE-HF trial, conducted in New Orleans, tested whether dapagliflozin, an SGLT2 inhibitor, could reduce the burden of atrial fibrillation (AF) after catheter ablation. AF remains a leading heart rhythm disorder, and recurrence after ablation poses a persistent challenge for patients and clinicians. While SGLT2 inhibitors…
-
Stopping DOACs After Successful AF Ablation: OCEAN Trial Feasible in Low-Risk Patients
Overview: Rethinking Anticoagulation After AF Ablation New data from the OCEAN trial suggest that stopping direct oral anticoagulants (DOACs) after a successful atrial fibrillation (AF) ablation may be feasible for low-risk patients. This challenges the long-standing practice of continuing anticoagulation based solely on prior AF history and CHADS2‑VASc scoring, and invites clinicians to re-evaluate individual…
-
Stopping DOACs After AF Ablation: OCEAN Trial Findings
New Evidence Suggests DOACs May Be Stopped After Successful AF Ablation in Low-Risk Patients A new analysis from the OCEAN trial presents a provocative finding for clinicians and patients managing atrial fibrillation (AF): for low-risk individuals who have undergone successful AF ablation, continuing oral anticoagulants (DOACs) may not offer a clear advantage in preventing stroke…
-
Stopping DOACs After Successful AF Ablation: Feasible in Low-Risk Patients? Insights from OCEAN Trial
New Evidence Questions Long-Term Anticoagulation After AF Ablation For patients with atrial fibrillation (AF) who undergo successful ablation, clinicians often face the question: should a patient continue taking a direct oral anticoagulant (DOAC) or switch to an antiplatelet strategy like aspirin? The OCEAN trial, presented in New Orleans, Louisiana, provides new data suggesting that, among…
-
Fit older male cyclists face these hidden heart risks — and why riding still matters
Why cycling remains beneficial for older adults Regular cycling is widely recognized for its cardiovascular benefits, from improving heart health to aiding weight management and mental well-being. For many older adults, cycling is a low-impact way to stay active, support joint health, and maintain independence. Yet, like any high-endurance sport, long-term, high-intensity cycling can introduce…
-
DOAC Outcomes in NVAF Linked to Echocardiographic Hemodynamics
Overview: DOACs, NVAF, and the role of cardiac hemodynamics Non-valvular atrial fibrillation (NVAF) requires careful stroke prevention, with direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran replacing warfarin in many patients. While DOACs have demonstrated non-inferiority to warfarin in large trials, real-world data reveal nuances in bleeding and stroke risk that may hinge…
-
Genetic Link: ADHD and Autism Raise Heart Disease Risk
Genetic predispositions and heart health: what the study found A comprehensive analysis of genetic data suggests that people with a genetic predisposition to attention deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) may face an increased risk of certain heart diseases. The study, which combines results from 14 separate investigations and was published in a…
-
Lack of Benefit from Surgical Left Atrial Appendage Occlusion in Non-AF Patients After Valve Surgery
**Understanding Surgical Left Atrial Appendage Occlusion** Surgical left atrial appendage occlusion (LAAO) is a procedure often considered to prevent complications such as ischemic strokes and transient ischemic attacks (TIAs). Traditionally, this procedure is recommended for patients with atrial fibrillation (AF), a condition marked by irregular heartbeats. However, recent studies challenge the utility of LAAO in…